# Volrustomig Priming Regimens Exploratory Phase II Platform Study

Source: https://onco.cc/trials/nct06448754/  
OnCo record `nct06448754` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Carboplatin, Pemetrexed, Ramucirumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Volrustomig Priming Regimens Exploratory Phase II Platform Study is a phase 2 interventional study registered as NCT06448754 by AstraZeneca, with 194 participants enrolled, started 2024-08-27 and due to reach its primary completion in 2027-07-30. Interventions recorded: Volrustomig, Carboplatin, Pemetrexed, Ramucirumab, Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06448754
- Phase: 2
- Setting: A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors (eVOLVE-01)
- Sponsor: AstraZeneca
- Enrolled: 194

## Sources

- ClinicalTrials.gov NCT06448754: https://clinicaltrials.gov/study/NCT06448754

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06448754.json